Group 1 - The medical beauty sector rose by 1.64% on August 11, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3647.55, up 0.34%, while the Shenzhen Component Index closed at 11291.43, up 1.46% [1] - The trading volume and turnover for key stocks in the medical beauty sector were as follows: Ai Meike (25,700 hands, 478 million yuan), Huaxi Biological (38,100 hands, 202 million yuan), Jinbo Biological (7,768 hands, 24.7 million yuan), and *ST Meigu (89,200 hands, 27.53 million yuan) [1] Group 2 - The net capital flow in the medical beauty sector showed a net outflow of 9.1 million yuan from institutional investors, while retail investors had a net inflow of 7.89 million yuan [1] - The individual stock capital flow indicated that Ai Meike had a net outflow of 11.18 million yuan, while *ST Meigu experienced a net inflow of 4.11 million yuan [2]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of differentiated membership stores, such as the WS Jiangtun membership store launched by Wushang Group in Wuhan, which focuses on unique products and services [5][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in sectors like gold jewelry, offline retail, cosmetics, and medical aesthetics [8][29] Summary by Sections Retail Market Review - The retail industry index reported a decline of 0.38% for the week of August 4 to August 8, 2025, underperforming the Shanghai Composite Index, which increased by 2.11% [14][21] - The jewelry sector showed the highest growth among retail sub-sectors, with a weekly increase of 6.07% and a year-to-date increase of 32.99% [16][19] Retail Insights - Wushang Group's WS Jiangtun membership store adopts a "paid membership + selected products" model, aiming to provide a differentiated shopping experience [5][24] - The store features a dual membership structure with basic and diamond tiers, enhancing customer engagement and loyalty [25] Investment Recommendations - Focus on gold jewelry brands with differentiated product offerings and consumer insights, recommending companies like Laopu Gold and Chaohongji [8][29] - Highlight the potential of offline retail companies that adapt to consumer trends, recommending Yonghui Supermarket and Aiyingshi [8][29] - Emphasize the growth of domestic cosmetics brands, recommending companies like Maogeping and Pola [8][29] - Suggest investment in medical aesthetics firms with differentiated product lines, recommending Aimeike and Kedi-B [8][29] Company Performance Highlights - Laopu Gold achieved a revenue of 8.506 billion yuan in FY2024, with a net profit increase of 253.9% [31][36] - Yonghui Supermarket reported a revenue of 17.479 billion yuan in Q1 2025, with a significant decline in net profit [31] - Chaohongji's Q1 2025 revenue increased by 25.4%, driven by its focus on fashion jewelry [43]

Core Viewpoint - The dispute over the exclusive agency rights for the "童颜针" (AestheFill) between *ST Suwu and Aimeike highlights the lucrative nature of the medical beauty industry, particularly the significant revenue generated by AestheFill for *ST Suwu, which could be jeopardized by the termination of the agency agreement [1][2][8]. Group 1: Agency Dispute - Aimeike announced the termination of the exclusive distribution agreement for AestheFill, which affects *ST Suwu's subsidiary, Datuo Medical, potentially leading to a loss of significant revenue [2][3]. - The reasons for the termination include alleged violations of the agreement by Datuo Medical and serious legal issues faced by *ST Suwu's executives, which have impacted the reputation of AestheFill in China [3][5]. - *ST Suwu refuted these claims, asserting that there was no transfer of agency rights and that the termination was unjustified, indicating potential legal actions against Aimeike [5][6]. Group 2: Financial Impact - AestheFill contributed over 3 billion yuan in revenue to *ST Suwu within a year, representing a 4000% increase in the medical beauty segment's performance [1][8]. - If the agency agreement is terminated, *ST Suwu anticipates a significant decline in revenue and profit from its medical beauty segment, with AestheFill projected to account for 20.42% of total revenue in 2024 [8][11]. - Aimeike's corresponding product, "濡白天使," has also shown strong performance, with revenues increasing from 385 million yuan in 2021 to 1.216 billion yuan in 2024, indicating robust growth in the medical beauty market [13]. Group 3: Market Dynamics - The medical beauty injection market, particularly for products like AestheFill, is expected to grow rapidly, with projections estimating a market size of 11.52 billion yuan by 2027 and a compound annual growth rate of 54.73% from 2021 to 2025 [9]. - The competition in the "童颜针" market is intensifying, with multiple players entering the space, including products from Aimeike, Korean REGEN, and others, indicating a crowded and competitive landscape [15].

Market Overview - The Shanghai Composite Index rose by 0.16% on August 7, with 18 out of 28 sectors experiencing gains, led by the non-ferrous metals and beauty care sectors, which increased by 1.20% and 0.99% respectively [1] - The pharmaceutical and electrical equipment sectors saw the largest declines, with decreases of 0.92% and 0.74% respectively [1] Fund Flow Analysis - The main funds in the two markets experienced a net outflow of 37.824 billion yuan, with 8 sectors seeing net inflows [1] - The electronics sector had the highest net inflow of 3.124 billion yuan, rising by 0.45%, followed by the non-ferrous metals sector with a net inflow of 650 million yuan and a daily increase of 1.20% [1] Beauty Care Sector Performance - The beauty care sector increased by 0.99% despite a net outflow of 37.9182 million yuan in main funds [2] - Out of 31 stocks in the beauty care sector, 21 stocks rose, including one that hit the daily limit, while 8 stocks fell, with one hitting the lower limit [2] - The top three stocks with the highest net inflow in the beauty care sector were Aimeike (714.056 million yuan), Lafang Jiahua (597.061 million yuan), and Shuiyang Co. (424.243 million yuan) [2][3] Notable Stocks in Beauty Care Sector - The stock "Beijia Jie" saw the largest net outflow of 261.5248 million yuan, with a decline of 10.01% [2] - Other notable stocks with significant net outflows included "Runben Co." and "Haoyue Care," with outflows of 21.2646 million yuan and 18.7484 million yuan respectively [2]

Group 1 - The A-share pharmaceutical sector is experiencing a rebound, with the Medical Innovation ETF (516820.SH) rising by 0.78% [1] - Key stocks such as Antu Bio (603658) increased by 6.18%, Mindray Medical (300760) by 2.61%, and Aimeike (300896) by 1.88% [1] - The Shanghai Regulatory Bureau and seven other ministries issued measures to promote the high-quality development of commercial insurance to support pharmaceutical innovation, encouraging the establishment of "patient capital" for long-term support of innovative drug research and development [1] Group 2 - The new measures have attracted over 100 drug applications for inclusion in the commercial health insurance innovative drug catalog, shifting the industry from a "single-driver" model to a "dual-driver" model of "medical insurance + commercial insurance" [1] - The national unified medical insurance big data platform, covering 1.3 billion insured individuals and over 300,000 types of drugs and consumables, is seen as a significant support for the development of the industry [1] - The platform aids in quickly analyzing clinical needs, enhancing drug value assessment, and accelerating the inclusion of innovative drugs into medical insurance, thus promoting the development of commercial insurance [1] Group 3 - Market dynamics are shifting, with funds moving from high-valued sectors to reasonably valued ones, leading to a gradual rebound of core assets at the bottom [2] - The medical innovation sector, including CXO (WuXi AppTec/TigerMed), medical devices (Mindray), and medical consumption (Aier Eye Hospital/Aimeike), is highlighted as having core assets that are significantly undervalued [2] - Weak U.S. economic and employment data may accelerate the Federal Reserve's rate cuts, enhancing global liquidity and benefiting technology stocks, presenting a good opportunity for investment in the medical innovation ETF (516820) [2]

Group 1 - The medical beauty sector increased by 0.16% on August 6, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3633.99, up 0.45%, while the Shenzhen Component Index closed at 11177.78, up 0.64% [1] - Key stocks in the medical beauty sector showed varied performance, with Jinbo Biological closing at 328.28, up 0.90%, and Aimeike slightly down by 0.03% [1] Group 2 - The medical beauty sector experienced a net outflow of 171.11 thousand yuan from main funds, while retail funds saw a net outflow of 668.85 thousand yuan [1] - The table indicates that *ST Meigu had a main fund inflow of 145.78 thousand yuan but a significant outflow from retail investors [2] - Huaxi Biological and Aimeike also showed mixed fund flows, with Huaxi experiencing a net outflow from main funds and a small inflow from retail investors [2]

Group 1 - The company, Aimeike, confirmed on August 5 that it has been supplying products normally after acquiring the South Korean company REGEN, adhering to its current production capacity [2] - The company's performance targets are evaluated based on unified standards, regardless of whether the products are domestic or from South Korea [2] - All products must comply with the regulatory requirements of each country for registration [2]

证券之星消息，8月5日医疗美容板块较上一交易日上涨0.41%，锦波生物领涨。当日上证指数报收于 3617.6，上涨0.96%。深证成指报收于11106.96，上涨0.59%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净点比 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 271.70万 | 17.26% | -314.88万 | -20.00% | 43.17万 | 2.74% | | 300896 爱美客 | -244.71万 | -0.61% | 2272.19万 | 5.64% | -2027.48万 | -5.04% | | 688363 华熙生物 | -618.47万 | -4.84% | 768.54万 | 6.01% | -150.07万 | -1.17% | 从资金流向上来看，当日医疗美容板块主力资金净流出591.48万元，游资资金净流入2725.85万元，散户 资金净流出2134.38万元。医疗美容板块个股资金流向见下表： ...

证券之星消息，8月4日医疗美容板块较上一交易日下跌0.9%，*ST美谷领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出5284.74万元，游资资金净流入2440.66万元，散户 资金净流入2844.08万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 183.25 | -0.69% | 2.05万 | 3.73 Z | | 832982 | 锦波生物 | 319.85 | -0.95% | 7186.67 | 2.30 Z | | 688363 | 华熙生物 | 51.35 | -1.15% | 2.85万 | 1.46 Z | | 000615 | *ST美谷 | 3.0 ...

转自：前瞻产业研究院 行业主要上市公司：爱美客(300896)、昊海生科(688366)、华熙生物(688363)、奥园美谷(000615)、华东 医药(000963)、朗姿股份(002612)、华韩整形(430335)等 本文核心数据：医疗美容行业全产业链;区域热力图;代表性企业产业链布局 1、医疗美容行业产业链全景梳理 我国医疗美容行业起步较晚，但发展迅速。中国医疗美容产业链上游主要包括医美原料供应商和医美器 材提供商;中游包括公立机构和民营机构，其中公立机构主要是指公立医院的整容科、专业医疗美容医 院等，民营机构是指大型连锁医美集团、中小型民营医美机构、私人诊所和美容院等;医美行业下游则 是消费者，主要可以根据需求分为多类。 我国医疗美容上游原料厂商主要有华熙生物、爱美客、昊海生科、华东医药、焦点生物等，医疗美容器 械主要是国外的医美器械龙头厂商;中游医美机构主要有华韩整形、丽都整形、瑞丽医美、鹏爱医疗等 机构，新兴的医美平台有新氧、更美、悦美等互联网平台;下游主要是广大的医疗美容消费者。 2、中国医疗美容产业链区域热力地图 从医疗美容行业产业链代表性企业分布来看，沿海地区代表企业分布较为密集，且产业链 ...